Vermindert duloxetine de neuropathische pijn bij patiënten met het centrale pijnsyndroom? Een dubbelblind gerandomiseerd onderzoek.
Completed
- Conditions
- 1. Central pain<br /> 2. duloxetine<br />3. quality of life<br />4. spinal cord lesion.<br />(NLD: centrale pijn, kwaliteit van leven, ruggenmergtrauma).
- Registration Number
- NL-OMON23743
- Lead Sponsor
- Academic Medical Center- Department of anesthesiology - Pain relief Unit. Meibergdreef 9, 1105 AZ, Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
1. Age 18 years or older;
2. Written informed consent;
Exclusion Criteria
1. Pregnant;
2. Had a history of intolerance, hypersensitivity, or known allergy to duloxetine;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary efficacy parameter is a pain intensity score recorded by patients (at baseline, and 8 weeks following treatment), using a visual analog scale (VAS).
- Secondary Outcome Measures
Name Time Method Health status and quality of life (QOL) questionnaires (secondary outcomes) are to be completed before start of treatment and 8 weeks following start of treatment. Health status and QOL measurements include the Pain Disability Index (PDI), the EQ-5D, and the Medical Outcomes Short-form Health Survey questionnaire 36 (SF36).